Skip to main content
SpringerLink
Log in

Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside

  • Omics, Markers, and Mechanisms
  • Published:
Translational Stroke Research Aims and scope Submit manuscript

Abstract

Tissue plasminogen activator (tPA) is the only FDA-approved medical therapy for acute ischemic stroke. But as a serine peptidase, intravenous tPA can affect the expression of other proteases that may be implicated in blood–brain barrier breakdown. Such parallel cascades of cell signaling may be involved in intracranial hemorrhage, the major side effect of tPA. Here, we describe an initial attempt in proteomic substrate profiling, i.e., degradomics in human plasma within the context of acute stroke. Plasma from acute stroke patients were analyzed pre- and post-intravenous tPA using tandem mass spectrometry and protein array profiling to identify substrates and proteases of interest. In non-tPA-treated stroke plasma, degradomic patterns indicated a rapid induction of protease activity within 3 h of stroke onset that mostly stabilized by 24 h. But in tPA-treated patients, pre- and post-tPA samples from the same patient demonstrated distinct degradomic patterns that persisted even up to 3–5 days after stroke onset. Matching control patients without strokes had little change in degradomic profiles over time. Our findings demonstrate that tPA treatment changes the plasma degradomic profiles in acute stroke patients. These composite proteolytic profiles may provide a glimpse of the pleiotropic effects of tPA on cellular signaling cascades at the bedside. This study supports the feasibility of performing pharmacoproteomics at the bedside, which may ultimately allow us to dissect mechanisms of thrombolysis-related therapeutic efficacy in stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7

    Google Scholar 

  2. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA stroke survey group. Neurology. 1999;53:424–7.

    CAS  PubMed  Google Scholar 

  3. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151–8.

    Article  CAS  PubMed  Google Scholar 

  4. Marler JR, Goldstein LB. Stroke - tPA and the clinic. Science 2003;301:1677

    Google Scholar 

  5. Hill MD, Buchan AM. Methodology for the Canadian activase for stroke effectiveness study (cases). Cases investigators. Can J Neurol Sci. 2001;28:232–8.

    CAS  PubMed  Google Scholar 

  6. Albers GW, Clark WM, Madden KP, Hamilton SA. Atlantis trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke. 2002;33:493–5.

    Article  PubMed  Google Scholar 

  7. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.

    Article  PubMed  Google Scholar 

  8. Donnan GA, Hommel M, Davis SM, McNeil JJ. Streptokinase in acute ischaemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. Lancet. 1995;346:56.

    Article  CAS  PubMed  Google Scholar 

  9. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, et al. Termination of trial of streptokinase in severe acute ischaemic stroke. MAST study group. Lancet. 1995;345:57.

    Article  CAS  PubMed  Google Scholar 

  10. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282:2019–26.

    Article  CAS  PubMed  Google Scholar 

  11. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.

    Article  PubMed  Google Scholar 

  12. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.

    Article  CAS  PubMed  Google Scholar 

  13. Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095–102.

    Article  CAS  PubMed  Google Scholar 

  14. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–703.

    Article  CAS  PubMed  Google Scholar 

  15. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002;33:1551–6.

    Article  PubMed  Google Scholar 

  16. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34:40–6.

    Article  CAS  PubMed  Google Scholar 

  17. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598–603.

    Article  CAS  PubMed  Google Scholar 

  18. Ebinger M, Iwanaga T, Prosser JF, De Silva DA, Christensen S, Collins M, et al. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. Stroke. 2009;40:2572–4.

    Article  PubMed  Google Scholar 

  19. Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C, et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010;41:72–7.

    Article  PubMed  Google Scholar 

  20. De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS, et al. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (epithet). Stroke. 2010;41:295–9.

    Article  PubMed  Google Scholar 

  21. De Silva DA, Ebinger M, Christensen S, Parsons MW, Levi C, Butcher K, et al. Baseline diabetic status and admission blood glucose were poor prognostic factors in the epithet trial. Cerebrovasc Dis. 2010;29:14–21.

    Article  PubMed  Google Scholar 

  22. Hemmen TM, Rapp KS, Emond JA, Raman R, Lyden PD. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria. J Stroke Cerebrovasc Dis. 2010;19:290–3.

    Article  PubMed  Google Scholar 

  23. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313–7.

    Article  CAS  PubMed  Google Scholar 

  24. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762–7.

    Article  CAS  PubMed  Google Scholar 

  25. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21:7724–32.

    CAS  PubMed  Google Scholar 

  26. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360–6.

    Article  CAS  PubMed  Google Scholar 

  27. Pfefferkorn T, Rosenberg GA. Closure of the blood–brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003;34:2025–30.

    Article  PubMed  Google Scholar 

  28. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999;842:92–100.

    Article  CAS  PubMed  Google Scholar 

  29. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373–8.

    Article  CAS  PubMed  Google Scholar 

  30. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034–40.

    CAS  PubMed  Google Scholar 

  31. Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke. 2001;32:1341–8.

    CAS  PubMed  Google Scholar 

  32. Abilleira S, Montaner J, Molina CA, Monasterio J, Castillo J, Alvarez-Sabin J. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg. 2003;99:65–70.

    Article  CAS  PubMed  Google Scholar 

  33. Ning M, Lo EH, Furie K, Koroshetz W, Sleeper L, Wang X, et al. T-pa-mediated increase in matrix metalloproteinase-9 in acute ischemic stroke is independent of inflammatory response. Stroke. 2004;35:298.

    Google Scholar 

  34. Heiss WD. Experimental evidence of ischemic thresholds and functional recovery. Stroke. 1992;23:1668–72.

    CAS  PubMed  Google Scholar 

  35. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002;3:509–19.

    Article  CAS  PubMed  Google Scholar 

  36. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest. 2006;116:26–30.

    Article  CAS  PubMed  Google Scholar 

  37. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.

    Article  CAS  PubMed  Google Scholar 

  38. Van Eyk JE, Dunn MJ. Clinical proteomics: from diagnosis to therapy. New York: Wiley; 2008

  39. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163–72.

    Article  CAS  PubMed  Google Scholar 

  40. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, et al. Blood–brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke. 2004;41:e123–8.

    Article  Google Scholar 

  41. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood–brain barrier disruption. Stroke. 2004;35:2659–61.

    Article  PubMed  Google Scholar 

  42. Hornig CR, Busse O, Dorndorf W, Kaps M. Changes in csf blood–brain barrier parameters in ischaemic cerebral infarction. J Neurol. 1983;229:11–6.

    Article  CAS  PubMed  Google Scholar 

  43. Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, et al. Serum transthyretin monomer as a possible marker of blood-to-csf barrier disruption. J Neurosci. 2003;23:1949–55.

    CAS  PubMed  Google Scholar 

  44. Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol. 2004;14:202–9.

    Article  CAS  PubMed  Google Scholar 

  45. Ning M, Wang X, Lo EH. Reperfusion injury after stroke: neurovascular proteases and the blood–brain barrier. Handb Clin Neurol. 2008;92:117–36.

    Article  Google Scholar 

  46. Arrell DK, Neverova I, Van Eyk JE. Cardiovascular proteomics: evolution and potential. Circ Res. 2001;88:763–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study is supported in part by NIH grants K23-NS51588, R21-NS52498, R01-NS67139, R37-NS37074, and P01-NS55104.

Author information

Authors and Affiliations

  1. Department of Neurology, Clinical Proteomics Research Center and Neuroprotection Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    MingMing Ning

  2. Departments of Neurology and Radiology, Clinical Proteomics Research Center and Neuroprotection Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    David A. Sarracino, Ferdinando S. Buonanno, Bryan Krastins, Sherry Chou, David McMullin, Xiaoying Wang, Mary Lopez & Eng H. Lo

Authors
  1. MingMing Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Sarracino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferdinando S. Buonanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bryan Krastins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sherry Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David McMullin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mary Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eng H. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to MingMing Ning or Eng H. Lo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ning, M., Sarracino, D.A., Buonanno, F.S. et al. Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside. Transl. Stroke Res. 1, 268–275 (2010). https://doi.org/10.1007/s12975-010-0047-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12975-010-0047-z

Keywords

Search

Navigation